Breast cancer molecular subtypes, i.e., based on the estrogen receptor (ER), progesterone receptor (PR) and receptor tyrosine-protein kinase erbB-2 (HER2) expression profiles, have helped in unraveling the heterogeneity nature of the disease. This evidence concerns the gene ERBB2 and breast carcinoma.